Caribou Biosciences Inc (CRBU)vsInsmed Inc (INSM)
CRBU
Caribou Biosciences Inc
$1.82
-2.15%
HEALTHCARE · Cap: $180.71M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 5334% more annual revenue ($606.42M vs $11.16M). CRBU leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CRBU
Avoid33
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 89.7% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 89.7% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CRBU
The primary concerns for CRBU are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CRBU profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.55 — expect wider price swings.
CRBU is growing revenue faster at 89.7% — sustainability is the question.
CRBU generates stronger free cash flow (-21M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology company specializing in the development of CRISPR-based therapies for genetic disorders and cancer. Leveraging its proprietary genome-editing technology, Caribou is dedicated to advancing precision medicine through a robust pipeline of innovative product candidates that address significant unmet medical needs. With a network of strategic partnerships enhancing its research capabilities, the company is well-positioned to make a transformative impact in the biopharmaceutical sector, ultimately striving to redefine treatment paradigms and improve patient outcomes.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?